WO2014003319A1 - 고농도의 줄기세포 제조방법 - Google Patents
고농도의 줄기세포 제조방법 Download PDFInfo
- Publication number
- WO2014003319A1 WO2014003319A1 PCT/KR2013/004517 KR2013004517W WO2014003319A1 WO 2014003319 A1 WO2014003319 A1 WO 2014003319A1 KR 2013004517 W KR2013004517 W KR 2013004517W WO 2014003319 A1 WO2014003319 A1 WO 2014003319A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- medium
- stem cells
- cells
- stem cell
- cell
- Prior art date
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 77
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 13
- 239000002609 medium Substances 0.000 claims description 76
- 210000004027 cell Anatomy 0.000 claims description 55
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 40
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 38
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 28
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 28
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 27
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 25
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 25
- 102000004877 Insulin Human genes 0.000 claims description 20
- 108090001061 Insulin Proteins 0.000 claims description 20
- 229940125396 insulin Drugs 0.000 claims description 20
- 239000011669 selenium Substances 0.000 claims description 20
- 229910052711 selenium Inorganic materials 0.000 claims description 20
- 235000011649 selenium Nutrition 0.000 claims description 20
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 19
- 229960000890 hydrocortisone Drugs 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- 235000010323 ascorbic acid Nutrition 0.000 claims description 14
- 239000011668 ascorbic acid Substances 0.000 claims description 14
- 229960005070 ascorbic acid Drugs 0.000 claims description 14
- 210000000577 adipose tissue Anatomy 0.000 claims description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 239000003963 antioxidant agent Substances 0.000 claims description 9
- 235000006708 antioxidants Nutrition 0.000 claims description 9
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 9
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 9
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims description 7
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 7
- 229940116977 epidermal growth factor Drugs 0.000 claims description 7
- 230000002608 insulinlike Effects 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- 229920002971 Heparan sulfate Polymers 0.000 claims description 4
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 4
- 239000007640 basal medium Substances 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229960003957 dexamethasone Drugs 0.000 claims description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 4
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 4
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 4
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 2
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 2
- 235000013734 beta-carotene Nutrition 0.000 claims description 2
- 239000011648 beta-carotene Substances 0.000 claims description 2
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 2
- 229960002747 betacarotene Drugs 0.000 claims description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000005487 catechin Nutrition 0.000 claims description 2
- 229950001002 cianidanol Drugs 0.000 claims description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 2
- 230000001605 fetal effect Effects 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 235000012661 lycopene Nutrition 0.000 claims description 2
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 2
- 229960004999 lycopene Drugs 0.000 claims description 2
- 239000001751 lycopene Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 229940091258 selenium supplement Drugs 0.000 claims description 2
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims 1
- 125000003748 selenium group Chemical group *[Se]* 0.000 claims 1
- 238000002659 cell therapy Methods 0.000 abstract description 2
- 210000001519 tissue Anatomy 0.000 description 20
- 239000002253 acid Substances 0.000 description 9
- 210000004504 adult stem cell Anatomy 0.000 description 9
- 239000000306 component Substances 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 108060005980 Collagenase Proteins 0.000 description 5
- 102000029816 Collagenase Human genes 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 4
- 229960002424 collagenase Drugs 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000007443 liposuction Methods 0.000 description 3
- 239000012092 media component Substances 0.000 description 3
- 210000002894 multi-fate stem cell Anatomy 0.000 description 3
- 210000001778 pluripotent stem cell Anatomy 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 108010076089 accutase Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 210000001691 amnion Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 108010007093 dispase Proteins 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000012533 medium component Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 101001004391 Drosophila melanogaster Protein jim lovell Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000004140 Oncostatin M Human genes 0.000 description 1
- 108090000630 Oncostatin M Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000012914 anti-clumping agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 108700014844 flt3 ligand Proteins 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000004728 pyruvic acid derivatives Chemical class 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000003014 totipotent stem cell Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
- C12N2500/33—Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/33—Insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2511/00—Cells for large scale production
Definitions
- the present invention relates to a method for producing a high concentration of stem cells, and more particularly to a method for proliferating stem cells in a high yield to be applicable to the clinical.
- Stem cells are cells that have the ability to self-replicate and differentiate into two or more cells, and are totipotent stem cells, pluripotent stem cells, and multipotent stem cells. can be classified as a multipotent stem cell.
- Pluripotent stem cells are pluripotent cells that can develop into a complete individual. Cells up to 8-cells after fertilization of eggs and sperm have these properties. Transplantation can result in one complete individual.
- Pluripotent stem cells are cells that can develop into various cells and tissues derived from ectoderm, mesoderm, and endodermal layer.Inner cell masses located inside the blastocyst appearing after 4-5 days of fertilization.
- Multipotent stem cells are stem cells that can only differentiate into cells specific to the tissues and organs that contain them, as well as the growth and development of individual tissues and organs in the prenatal, neonatal, and adult phases. It is involved in maintaining homeostasis of adult tissues and inducing regeneration in case of tissue damage and collectively called tissue-specific pluripotent cells are called adult stem cells.
- the present inventors have made diligent efforts for mass production of stem cells, basal medium; And N-acetyl-L-cysteine (NAC), ascorbic acid, insulin or insulin like factor, hydrocortisone, basic fibroblast growth factor (bFGF), epidermal growht factor (EGF), and antioxidants. After culturing the stem cells in a medium containing two or more components, it was confirmed that the stem cells can be grown to a high concentration in a short time, and the present invention was completed.
- N-acetyl-L-cysteine NAC
- ascorbic acid insulin or insulin like factor
- hydrocortisone hydrocortisone
- bFGF basic fibroblast growth factor
- EGF epidermal growht factor
- An object of the present invention to provide a method for producing a high concentration of stem cells in a short time.
- the present invention is a basic medium for stem cells; And N-acetyl-L-cysteine (NAC), ascorbic acid, insulin or insulin like factor, hydrocortisone, dexamethasone, basic fibroblast growth factor (bFGF), heparan sulfate, 2-mer It provides a method for producing a high concentration of stem cells, comprising the step of culturing the stem cells in a medium containing two or more components selected from the group consisting of 2-mercaptoethanol, EGF (epidermal growth factor) and antioxidants .
- Figure 1 shows the cell population doubling level of the adipose derived stem cells obtained from adult men in their twenties, thirties, seventies, and eighties for four days in each medium composition.
- stem cell used in the present invention refers to a cell having the ability of self-replicating and differentiating into two or more cells, and an "adult stem cell” refers to each organ of the embryo during the development process. Refers to stem cells appearing in the stage of formation or adulthood.
- the term “mesenchymal stem cell” is an undifferentiated stem cell isolated from human or mammalian tissue, and may be derived from various tissues.
- umbilical cord-derived mesenchymal stem cells umbilical cord blood-derived mesenchymal stem cells, bone marrow-derived mesenchymal stem cells, adipose-derived mesenchymal stem cells, muscle-derived mesenchymal stem cells, nerve-derived mesenchymal stem cells, skin-derived mesenchymal stem cells , Amnion derived mesenchymal stem cells and placental derived mesenchymal stem cells, and techniques for isolating stem cells from each tissue are already known in the art.
- fatty tissue-derived mesenchymal stem cells refers to undifferentiated adult stem cells isolated from adipose tissue, abbreviated herein as “fat-derived adult stem cells,” “fat stem cells,” or “fat. Derived stem cells ”. This can be obtained through conventional methods known in the art, and the separation method can be as follows, for example. In other words, the suspension containing fat suspended in physiological saline obtained from liposuction, and then treated with trypsin of the stem cell layer attached to the culture vessel, such as a flask and recovered or scraped with a scraper to directly float in a small amount of physiological saline. Adipose-derived mesenchymal stem cells can be separated by a method such as recovery.
- “high concentration stem cell production” means to multiply the number of stem cells in a high yield, and in this specification, “high concentration stem cells” may be referred to as “mass stem cells”.
- “mass stem cells” it was confirmed that the number of stem cells obtainable when cultured in the medium according to the present invention stem cells isolated from the tissues significantly increased. Preferably, it was confirmed that it is possible to obtain a three to five times when sub-cultured 10 7 ⁇ 5 ⁇ 10 8 The number of cells / ml of stem cells.
- passage culture means a method of continually cultivating the generation of cells while transferring a portion of the cells periodically to a new culture vessel in order to continuously cultivate the cells in a healthy state for a long time. do.
- proliferation of nutrients is consumed or contaminants accumulate, causing the cells to die naturally, which is used as a method for increasing the number of healthy cells.
- Replacing a culture vessel or dividing a cell population is called one passage.
- the method of subculture may be used without limitation methods known in the art, but may preferably be carried out by mechanical separation or enzymatic separation.
- mechanical separation means physically or mechanically separating a cell mass, and any method known in the art can be used without limitation, but preferably, a blade, a tissue chopper, The separation may be by using a needle, pipetting, or scraper. According to a preferred embodiment of the present invention it was confirmed that the stem cells were mass-proliferated by passage culture using a blade or tissue mill.
- “chemical separation” means to separate the cell mass through the enzyme treatment, and methods known in the art can be used without limitation, but preferably include collagenase I, II, III, IV
- the collagenase Collagenase
- Accutase Accutase
- Dispase Dispase
- trypsin trypsin
- Stem cells can be administered into the body in a variety of ways, for example, intravenous, intraarterial, or intraperitoneal administration, among which intravenous administration is useful because it is easy and safe to treat the disease without surgery.
- intravenous, intraarterial, or intraperitoneal administration among which intravenous administration is useful because it is easy and safe to treat the disease without surgery.
- various requirements must be satisfied.
- the administration of cells of a certain concentration or more must be premised so that the stem cells reaching the target site have the desired therapeutic effect. Therefore, it is important to obtain a large amount of stem cells to be clinically applied.
- the stem cells administered intravenously should be sized to be suitable for intravenous administration so as not to reduce the rate of blood flow or to form a thrombus.
- no cell breakage or aggregation should be formed before administration into the blood vessel, and even after administration into the blood vessel, the cells will stably reach the target site as a single cell without disruption or formation of aggregation. It must be
- the present invention is to provide a stem cell of a certain concentration or more to be effective in the clinical.
- the stem cell culture according to the conventional method in order to obtain a high yield of stem cells, it is necessary to carry out passage cultivation several times, which requires a lot of manpower and time. Particularly, some of the media components necessary for passage cultivation are very expensive and economically effective. There was also no advantage.
- the present invention is capable of producing a high concentration of stem cells that can be clinically applied only by three to five passages.
- the present invention in one aspect, in one aspect, the stem cell base medium; And N-acetyl-L-cysteine (NAC), ascorbic acid, insulin or insulin like factor, hydrocortisone, dexamethasone, basic fibroblast growth factor (bFGF), heparan sulfate, 2-mer
- NAC N-acetyl-L-cysteine
- ascorbic acid insulin or insulin like factor
- hydrocortisone hydrocortisone
- dexamethasone basic fibroblast growth factor (bFGF)
- bFGF basic fibroblast growth factor
- 2-mercaptoethanol epidermal growth factor
- Stem cells to be used in the present invention is preferably adult stem cells, especially adipose tissue, or adult stem cells obtained from epithelial tissue such as hair follicles, amniotic membranes can be used. Most preferably, adult stem cells derived from adipose tissue can be used.
- Mesenchymal stem cells (MSCs) may be used, and in particular, adipose tissue-derived mesencymal stem cells (AdMSCs) may be used. It is preferable that the said fat or epithelial tissue is derived from a mammal, and it is still more preferable that it is derived from a human. In one embodiment of the present invention, human adipose tissue-derived mesenchymal stem cells (AdMSCs) were used.
- Basal medium used in the present invention refers to a conventional medium having a simple composition known in the art as suitable for stem cell culture.
- Basic media commonly used for culture include MEM (Minimal Essential Medium), DMEM (Dulbecco modified Eagle Medium), RPMI (Roswell Park Memorial Institute Medium), and K-SFM (Keratinocyte Serum Free Medium). If the medium used in is enough.
- M199 / F12 (mixture) (GIBCO), MEM-alpha medium (GIBCO), low glucose containing DMEM medium (Welgene), MCDB 131 medium (Welgene), IMEM medium (GIBCO), K-SFM, DMEM / It may be selected from the group consisting of F12 medium, PCM medium and MSC expansion medium (Chemicon). In particular, among these, K-SFM medium can be used preferably.
- the basal medium used to obtain the mesenchymal stem cell culture may be supplemented with additives known in the art, which promote the proliferation of the undifferentiated phenotype of mesenchymal stem cells while inhibiting differentiation.
- the medium may contain neutral buffers (such as phosphates and / or high concentrations of bicarbonate) and protein nutrients (eg, serums such as FBS, fetal calf serum, horse serum, serum substitutes, albumin, or essential amino acids and non-essentials in isotonic solution).
- Amino acids such as glutamine, L-glutamine).
- lipids fatty acids, cholesterol, HDL or LDL extracts of serum
- other components found in most preservative media of this kind such as insulin or transferrin, nucleosides or nucleotides, pyruvate salts, any ionized form or salt
- Sugar sources such as glucose, selenium, glucocorticoids such as hydrocortisone and / or reducing agents such as ⁇ -mercaptoethanol.
- the medium also contains anti-clumping agents, such as those sold by Invitrogen (Cat # 0010057AE), with the aim of preventing the cells from adhering to each other, adhering to the vessel wall, or forming too large a bundle. It can be beneficial to do so.
- anti-clumping agents such as those sold by Invitrogen (Cat # 0010057AE)
- SCF Stem cell factor
- other ligands or antibodies that dimerize the c-kit and other active agents of the same signal transduction pathway
- tyrosine kinase related receptors such as platelet-Derived Growth Factor (PDGF), macrophage colony-stimulating factor, Flt-3 ligand and Vascular Endothelial Growth Factor (VEGF) Ligands for PDGF
- PDGF platelet-Derived Growth Factor
- macrophage colony-stimulating factor Flt-3 ligand
- VEGF Vascular Endothelial Growth Factor
- Hematopoietic hair growth factors such as thrombopoietin (TPO)
- Modified growth factors such as TGF ⁇ -1
- Neurotropins such as CNTF
- Antibiotics such as gentamicin, penicillin, streptomycin
- the medium used in the present invention is, in addition to the basic medium, N-acetyl-L-cysteine (NAC), ascorbic acid (ascorbic acid), insulin or insulin like factor, hydrocortisone, dexamethasone, basic fibroblast growth factor (bFGF), It may further contain two or more ingredients selected from the group consisting of heparan sulfate, 2-mercaptoethanol, epidermal growth factor (EGF) and antioxidants.
- NAC N-acetyl-L-cysteine
- ascorbic acid ascorbic acid
- insulin or insulin like factor hydrocortisone
- dexamethasone dexamethasone
- bFGF basic fibroblast growth factor
- It may further contain two or more ingredients selected from the group consisting of heparan sulfate, 2-mercaptoethanol, epidermal growth factor (EGF) and antioxidants.
- insulin-like factor as an alternative to insulin, which enhances glucose metabolism and protein metabolism to promote cell growth.
- IGF-1 Insulin-like growth factor-1
- the preferred amount of insulin-like factor is 10 to 50 ng / ml, and if its component is less than 10 ng / ml, it causes apoptosis, and if it exceeds 50 ng / ml, problems of cytotoxicity and cost increase are observed. have.
- fibroblast growth factor bFGF
- bFGF fibroblast growth factor
- the preferred content of fibroblast growth factor is 1 to 100 ng / ml.
- selenium As antioxidants, selenium, ascorbic acid, vitamin E, catechin, lycopene, beta carotene, coenzyme Q-10, EPA (eicosapentaenoic acid), DHA (docosahexanoic acid) can be used, and preferably selenium can be used. have.
- selenium was used as an antioxidant, and the amount of selenium used is preferably 0.5 to 10 ng / ml. At this time, if the content thereof is less than 0.5 ng / ml is sensitive to oxygen toxicity, if it exceeds 10 ng / ml because it causes severe cytotoxicity.
- the medium used in the present invention may further contain a component selected from the group consisting of FBS (fetal bovin serum), calcium and EGF.
- FBS fetal bovin serum
- EGF epidermal growth factor
- the preferred content of epidermal growth factor is 10 to 50 ng / ml, the content of which is less than 10 ng / ml has no particular effect, if it exceeds 50 ng / ml is toxic to cells.
- Stem cells cultured in the medium according to the present invention is preferably multiplied by the number of 1 ⁇ 10 7 to 5 ⁇ 10 8 cells / ml in three to five passages.
- the stem cells according to the present invention can be effectively applied to the clinic.
- adipose derived mesenchymal stem cells were cultured in the medium according to the present invention.
- Adipose-derived mesenchymal stem cells can be obtained by the following method. First, the human adipose tissue obtained from the abdomen by liposuction and the like is separated and washed with PBS, and then the tissue is chopped and digested with DMEM medium containing collagen degrading enzyme, followed by washing with PBS and at 1000 rpm. Centrifuge for 5 minutes. The supernatant is removed and the remaining pellets are washed with PBS and centrifuged at 1000 rpm for 5 minutes. The float was removed using a 100 ⁇ m mesh and then washed again with PBS.
- the adipose tissue obtained from the abdomen by liposuction was separated and washed with PBS.
- the washed adipose tissue was chopped and the tissue was digested at 37 ° C. for 2 hours using DMEM medium to which collagenase type 1 (1 mg / ml) was added.
- the collagenase treated tissues were washed with PBS, centrifuged at 1000 rpm for 5 minutes, the supernatant was removed, the pellet was washed with PBS and centrifuged at 1000 rpm for 5 minutes.
- Adipose-derived mesenchymal stem cells were cultured up to 4 passages with K-SFM media containing / ml of selenium every 2 days.
- FBS N-acetyl-L-cysteine
- NAC N-acetyl-L-cysteine
- bFGF basic fibroblast growth factor
- M1 K-SFM Medium + FBS + NAC + Asocorbic Acid + Insulin + Hydrocortisone + bFGF + EGF + Selenium
- M2 K-SFM medium + NAC + asocorbic acid + insulin + hydrocortisone + bFGF + EGF + selenium (excluding FBS in the composition of medium 1)
- M3 K-SFM medium + FBS + NAC + asocorbic acid + insulin + hydrocortisone + EGF + selenium (except bFGF in the composition of medium 1)
- M4 K-SFM medium + FBS + NAC + asocorbic acid + hydrocortisone + bFGF + EGF + selenium (excluding insulin in the composition of medium 1)
- Medium 5 K-SFM medium + FBS + NAC + asocorbic acid + insulin + bFGF + EGF + selenium (excluding hydrocortisone among the components of medium 1)
- M6 K-SFM medium + FBS + NAC + asocorbic acid + insulin + hydrocortisone + bFGF + selenium (excluding EGF in the composition of medium 1)
- Medium 7 K-SFM medium + FBS + NAC + insulin + hydrocortisone + bFGF + EGF + selenium (excluding ascorbic acid in the composition of medium 1)
- Medium 8 K-SFM medium + FBS + asocorbic acid + insulin + hydrocortisone + bFGF + EGF + selenium (excluding NAC in the composition of medium 1)
- M10 K-SFM medium + FBS + NAC + asocorbic acid + insulin + hydrocortisone + selenium (except bFGF and EGF in the composition of medium 1)
- Adipose derived stem cells were cultured in the medium.
- Adipose stem cells were obtained from adipose derived stem cells obtained from adult men in their 20s, 30s, 70s and 80s. In each medium, the obtained adipose-derived stem cells were passaged up to 4 passages, followed by trypsin treatment, and the number of cells was confirmed by a confocal microscope.
- Table 1 1 ⁇ 10 5 fat-derived mesenchymal stem cells of the third passage were inoculated and cultured for 4 days, and the number of cells obtained by medium and primary was expressed.
- stem cells up to 2.5 ⁇ 10 6 cells / ml could be prepared according to the medium component (Table 1).
- the media 9 had the highest cell population doubling level (CPDL) value.
- CPDL cell population doubling level
- the number of cells increased by 13 to 25 times.
- the number of cells was 7 to 15 times. It was confirmed that the increase (Fig. 1).
- cells in which mutations occurred were not identified (not shown).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Age | Post seedingDay | Total Cell Count (×104/ml) | |||||||||
M1 | M2 | M3 | M4 | M5 | M6 | M7 | M8 | M9 | M10 | ||
20 | Day0 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Day1 | 8 | 16 | 15 | 13 | 12 | 16 | 12 | 12 | 8 | 12 | |
Day2 | 39 | 13.5 | 30.5 | 38 | 29.5 | 33.5 | 39 | 30 | 26.5 | 9.5 | |
Day3 | 115 | 11.5 | 70 | 110 | 115 | 110 | 110 | 110 | 105 | 11 | |
Day4 | 230 | 10.5 | 135 | 195 | 180 | 225 | 250 | 230 | 205 | 13 | |
30 | Day0 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Day1 | 12 | 10 | 14 | 11 | 16 | 27 | 23 | 10 | 26 | 25 | |
Day2 | 35 | 12 | 24.5 | 40 | 40 | 35.5 | 33.5 | 39.5 | 41 | 10.5 | |
Day3 | 120 | 150 | 0 | 90 | 110 | 95 | 105 | 110 | 125 | 10.5 | |
Day4 | 215 | 10 | 150 | 185 | 130 | 165 | 230 | 220 | 220 | 13 | |
70 | Day0 | 10 | 10 | 10 | 1000 | 10 | 10 | 10 | 10 | 10 | 10 |
Day1 | 12 | 7 | 16 | 12 | 13 | 20 | 10 | 13 | 20 | 11 | |
Day2 | 37 | 9 | 31 | 32.5 | 27.5 | 29 | 29.5 | 30.5 | 26 | 13 | |
Day3 | 85 | 12 | 60 | 65 | 80 | 86 | 90 | 100 | 95 | 12 | |
Day4 | 155 | 7 | 85 | 120 | 135 | 105 | 145 | 150 | 155 | 13.5 | |
80 | Day0 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Day1 | 20 | 10 | 17 | 15 | 16 | 13 | 16 | 13 | 17 | 16 | |
Day2 | 24.5 | 11.5 | 16.5 | 21 | 19.5 | 26 | 17 | 24.5 | 23 | 10.5 | |
Day3 | 37 | 7.5 | 31 | 41 | 37 | 47 | 65 | 55 | 48.5 | 9 | |
Day4 | 75 | 9 | 55 | 90 | 70 | 70 | 65 | 80 | 65 | 14.5 |
Claims (6)
- 줄기세포를 기본배지; 및 NAC(N-acetyl-L-cysteine), 아소코르브산 (ascorbic acid), 인슐린 또는 인슐린 유사인자, 하이드로코르티손, 덱사메타손, bFGF (basic fibroblast growth factor), 헤파란 황산 (heparan sulfate), 2-메르캅토에탄올 (2-mercaptoethanol), EGF (epidermal growth factor) 및 항산화제로 구성된 군에서 선택되는 2가지 이상의 성분을 함유하는 배지에서 줄기세포를 3회 내지 5회 계대 배양하는 단계를 포함하는, 1 × 107 ~ 5 × 108 세포수/ml의 줄기세포 제조방법.
- 제1항에 있어서, 상기 기본 배지는 M199/F12(mixture)(GIBCO), MEM-alpha배지(GIBCO), 저농도 글루코오스 함유 DMEM배지(Welgene), MCDB 131배지(Welgene), IMEM배지(GIBCO), K-SFM, DMEM/F12 배지, PCM 배지 및 MSC 확장 배지 (Chemicon)로 구성된 군에서 선택되는 것을 특징으로 하는 1 × 107 ~ 5 × 108 세포수/ml 의 줄기세포 제조방법.
- 제1항에 있어서, 상기 항산화제는 셀레늄, 비타민 E, 카테킨, 라이코펜, 베타카로틴, 코엔자임 Q-10, EPA(eicosapentaenoic acid) 및 DHA(docosahexanoic acid)로 구성된 군에서 선택되는 것을 특징으로 하는 1 × 107 ~ 5 × 108 세포수/ml 의 줄기세포 제조방법.
- 제3항에 있어서, 상기 항산화제는 셀레늄인 것을 특징으로 하는 1 × 107 ~ 5 × 108 세포수/ml 의 줄기세포 제조방법.
- 제1항에 있어서, 상기 배지는 FBS (fetal bovin serum), 칼슘 및 EGF으로 구성된 군에서 선택되는 성분을 추가로 함유하는 것을 특징으로 하는 1 × 107 ~ 5 × 108 세포수/ml 의 줄기세포 제조방법.
- 제1항에 있어서, 상기 줄기세포는 지방 조직 유래 중간엽 줄기세포인 것을 특징으로 하는 1 × 107 ~ 5 × 108 세포수/ml 의 줄기세포 제조방법.
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2014014337A MX2014014337A (es) | 2012-06-26 | 2013-05-23 | Metodo de produccion de alta concentracion de celulas madre. |
EP13810037.5A EP2865749A4 (en) | 2012-06-26 | 2013-05-23 | PROCESS FOR PRODUCING HIGH-CONCENTRATION STEM CELLS |
US14/405,320 US20150118748A1 (en) | 2012-06-26 | 2013-05-23 | High-concentration stem cell production method |
AU2013281596A AU2013281596A1 (en) | 2012-06-26 | 2013-05-23 | High-concentration stem cell production method |
BR112014031874A BR112014031874A2 (pt) | 2012-06-26 | 2013-05-23 | método para preparar células-tronco em concentração elevada |
JP2015520000A JP2015526067A (ja) | 2012-06-26 | 2013-05-23 | 高濃度の幹細胞の製造方法 |
CN201380026928.0A CN104603263A (zh) | 2012-06-26 | 2013-05-23 | 高浓度干细胞的生产方法 |
ZA2014/08915A ZA201408915B (en) | 2012-06-26 | 2014-12-04 | High-concentration stem cell production method |
HK15107352.0A HK1206781A1 (en) | 2012-06-26 | 2015-07-31 | High-concentration stem cell production method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2012-0068796 | 2012-06-26 | ||
KR1020120068796A KR101523040B1 (ko) | 2012-06-26 | 2012-06-26 | 고농도의 줄기세포 제조방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014003319A1 true WO2014003319A1 (ko) | 2014-01-03 |
Family
ID=49783416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2013/004517 WO2014003319A1 (ko) | 2012-06-26 | 2013-05-23 | 고농도의 줄기세포 제조방법 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20150118748A1 (ko) |
EP (1) | EP2865749A4 (ko) |
JP (1) | JP2015526067A (ko) |
KR (1) | KR101523040B1 (ko) |
CN (1) | CN104603263A (ko) |
AU (1) | AU2013281596A1 (ko) |
BR (1) | BR112014031874A2 (ko) |
HK (1) | HK1206781A1 (ko) |
MX (1) | MX2014014337A (ko) |
WO (1) | WO2014003319A1 (ko) |
ZA (1) | ZA201408915B (ko) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101830062B1 (ko) * | 2017-06-30 | 2018-02-20 | 주식회사 차바이오텍 | 피부줄기세포 배양액을 포함하는 피부 노화 예방 또는 개선용 조성물 및 이의 용도 |
KR20190003303A (ko) * | 2017-12-26 | 2019-01-09 | (주) 차바이오에프앤씨 | 피부줄기세포 배양액을 포함하는 피부 노화 예방 또는 개선용 조성물 및 이의 용도 |
WO2019004800A3 (ko) * | 2017-06-30 | 2019-05-23 | 주식회사 차바이오텍 | 줄기세포 유래 피부전구세포 배양액 및 이의 제조 방법 |
US10640541B2 (en) | 2015-09-15 | 2020-05-05 | Stemlab Inc. | Method for preparing composition for promoting hair growth using Nanog-introduced mesenchymal stem cells derived from fetus in amniotic fluid |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2811015B1 (en) * | 2011-12-01 | 2020-09-02 | R Bio Co., Ltd. | Culture-medium composition for rejuvenating stem cells |
CN104520423B (zh) | 2012-04-18 | 2017-07-04 | K-干细胞有限公司 | 用于生产具有适于血管内给药的尺寸的干细胞的方法 |
CN105473706B (zh) | 2013-06-14 | 2021-10-26 | 昆士兰大学 | 肾祖细胞 |
KR101753557B1 (ko) | 2014-06-30 | 2017-07-05 | 가톨릭대학교 산학협력단 | 줄기세포 증식 향상 배지 조성물 및 줄기세포의 배양방법 |
CN106659741B (zh) * | 2014-07-07 | 2020-03-17 | 米迪波斯特股份有限公司 | 小尺寸干细胞的毛发生长促进功能及其用途 |
US10287551B2 (en) | 2014-10-29 | 2019-05-14 | R Bio Co., Ltd. | Medium composition for culturing stem cells |
US20180037867A1 (en) * | 2015-03-04 | 2018-02-08 | Mesoblast International Sàrl | Cell culture method for mesenchymal stem cells |
US10894947B1 (en) * | 2016-04-29 | 2021-01-19 | Hope Biosciences, Llc | Method for generating protein rich conditioned medium |
JP6918943B2 (ja) * | 2016-07-29 | 2021-08-11 | ラ,チョンチャン | 癌細胞の増殖を抑制する間葉幹細胞の製造方法 |
US11268950B2 (en) | 2016-09-28 | 2022-03-08 | Organovo, Inc. | Use of engineered renal tissues in assays |
EP3569239A4 (en) * | 2017-01-11 | 2020-12-09 | Stemlab Inc. | METHOD OF PREPARING A COMPOSITION IN AN EXOSOME FROM NANG-INTRODUCED FETAL MESENCHYMAL STEM CELL IN THE FRUIT WATER FOR HAIR GROWTH |
KR101878441B1 (ko) * | 2017-02-14 | 2018-07-16 | 경상대학교산학협력단 | 신생아 말초혈액 유래 중간엽 줄기세포의 분리 및 배양 방법 |
KR102025474B1 (ko) * | 2017-10-30 | 2019-09-25 | 사회복지법인 삼성생명공익재단 | 에티오나마이드를 이용한 줄기세포 이동성 향상 방법 |
US11932874B2 (en) * | 2018-05-25 | 2024-03-19 | R Bio Co., Ltd. | Method for culturing mesenchymal stem cells using gamma-irradiated serum |
KR102556520B1 (ko) * | 2019-07-15 | 2023-07-18 | 사회복지법인 삼성생명공익재단 | 에티오나마이드를 이용한 줄기세포의 효능 강화방법 |
CN111150746A (zh) * | 2020-01-06 | 2020-05-15 | 湖南护宫福生物科技有限公司 | 一种用于阴道给药治疗妇科炎症的干细胞修复液 |
CN113801836A (zh) * | 2020-06-16 | 2021-12-17 | 台湾粒线体应用技术股份有限公司 | 提升线粒体功能的培养方法及其使用的组合物 |
KR102439335B1 (ko) * | 2021-12-10 | 2022-09-02 | 주식회사 엠케이바이오텍 | 태반-유래 줄기세포를 함유하는 피부 재생용 바이오패치형 세포치료제 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6103530A (en) * | 1997-09-05 | 2000-08-15 | Cytotherapeutics, Inc. | Cultures of human CNS neural stem cells |
WO2006019357A1 (en) | 2004-08-16 | 2006-02-23 | Cellresearch Corporation Pte Ltd | Isolation of stem/progenitor cells from amniotic membrane of umbilical cord. |
KR100795708B1 (ko) | 2006-12-26 | 2008-01-17 | 주식회사 알앤엘바이오 | 인간 양막 상피세포 유래 성체 줄기세포의 분리 및 배양방법 |
KR100818214B1 (ko) | 2006-09-29 | 2008-04-01 | 재단법인서울대학교산학협력재단 | 인간 태반조직의 양막 또는 탈락막 유래 다분화능 줄기세포및 그 제조방법 |
KR20080075959A (ko) * | 2007-02-14 | 2008-08-20 | (주)프로스테믹스 | 지방 줄기세포의 조직 재생 능력을 최적화한 배양액을 함유한 조직 재생용 주사제 조성물 |
US20090124007A1 (en) * | 2006-11-15 | 2009-05-14 | Seoul National University Industry Foundation | Method for the Simultaneous Primary-Isolation and Expansion of Endothelial Stem/Progenitor Cell and Mesenchymal Stem Cell Derived From Mammal Including Human Umbilical Cord |
US20090233360A1 (en) * | 2008-03-17 | 2009-09-17 | Uti Limited Partnership | Methods and Compositions for Culturing of neural Precursor Cells |
US20110312091A1 (en) * | 2008-12-17 | 2011-12-22 | Baona Zhao | Pluripotent stem cells, method for preparation thereof and uses thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100679642B1 (ko) * | 2005-11-16 | 2007-02-06 | 주식회사 알앤엘바이오 | 인간 지방조직 유래 다분화능 줄기세포 및 이를 함유하는세포치료제 |
NZ595786A (en) * | 2005-12-29 | 2013-05-31 | Anthrogenesis Corp | Placental stem cell populations |
CN101473030A (zh) * | 2006-06-15 | 2009-07-01 | Rnl生物技术株式会社 | 含有来自人类脂肪组织的多塑性干细胞、成纤维细胞和脂肪或脂肪细胞的整容或整形组合物 |
JP2013529917A (ja) * | 2010-06-17 | 2013-07-25 | ステムアールディー, インコーポレイテッド | 化学的に定められている無血清細胞培養培地 |
KR101211913B1 (ko) * | 2010-07-16 | 2012-12-13 | 주식회사 알앤엘바이오 | 양막유래 중간엽 줄기세포 배양을 위한 배지조성물 및 이를 이용한 양막유래 중간엽 줄기세포의 배양방법 |
EP2811015B1 (en) * | 2011-12-01 | 2020-09-02 | R Bio Co., Ltd. | Culture-medium composition for rejuvenating stem cells |
-
2012
- 2012-06-26 KR KR1020120068796A patent/KR101523040B1/ko active IP Right Grant
-
2013
- 2013-05-23 US US14/405,320 patent/US20150118748A1/en not_active Abandoned
- 2013-05-23 EP EP13810037.5A patent/EP2865749A4/en not_active Withdrawn
- 2013-05-23 MX MX2014014337A patent/MX2014014337A/es unknown
- 2013-05-23 JP JP2015520000A patent/JP2015526067A/ja active Pending
- 2013-05-23 WO PCT/KR2013/004517 patent/WO2014003319A1/ko active Application Filing
- 2013-05-23 AU AU2013281596A patent/AU2013281596A1/en not_active Abandoned
- 2013-05-23 BR BR112014031874A patent/BR112014031874A2/pt not_active IP Right Cessation
- 2013-05-23 CN CN201380026928.0A patent/CN104603263A/zh active Pending
-
2014
- 2014-12-04 ZA ZA2014/08915A patent/ZA201408915B/en unknown
-
2015
- 2015-07-31 HK HK15107352.0A patent/HK1206781A1/xx unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6103530A (en) * | 1997-09-05 | 2000-08-15 | Cytotherapeutics, Inc. | Cultures of human CNS neural stem cells |
WO2006019357A1 (en) | 2004-08-16 | 2006-02-23 | Cellresearch Corporation Pte Ltd | Isolation of stem/progenitor cells from amniotic membrane of umbilical cord. |
KR100818214B1 (ko) | 2006-09-29 | 2008-04-01 | 재단법인서울대학교산학협력재단 | 인간 태반조직의 양막 또는 탈락막 유래 다분화능 줄기세포및 그 제조방법 |
US20090124007A1 (en) * | 2006-11-15 | 2009-05-14 | Seoul National University Industry Foundation | Method for the Simultaneous Primary-Isolation and Expansion of Endothelial Stem/Progenitor Cell and Mesenchymal Stem Cell Derived From Mammal Including Human Umbilical Cord |
KR100795708B1 (ko) | 2006-12-26 | 2008-01-17 | 주식회사 알앤엘바이오 | 인간 양막 상피세포 유래 성체 줄기세포의 분리 및 배양방법 |
KR20080075959A (ko) * | 2007-02-14 | 2008-08-20 | (주)프로스테믹스 | 지방 줄기세포의 조직 재생 능력을 최적화한 배양액을 함유한 조직 재생용 주사제 조성물 |
US20090233360A1 (en) * | 2008-03-17 | 2009-09-17 | Uti Limited Partnership | Methods and Compositions for Culturing of neural Precursor Cells |
US20110312091A1 (en) * | 2008-12-17 | 2011-12-22 | Baona Zhao | Pluripotent stem cells, method for preparation thereof and uses thereof |
Non-Patent Citations (1)
Title |
---|
See also references of EP2865749A4 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10640541B2 (en) | 2015-09-15 | 2020-05-05 | Stemlab Inc. | Method for preparing composition for promoting hair growth using Nanog-introduced mesenchymal stem cells derived from fetus in amniotic fluid |
KR101830062B1 (ko) * | 2017-06-30 | 2018-02-20 | 주식회사 차바이오텍 | 피부줄기세포 배양액을 포함하는 피부 노화 예방 또는 개선용 조성물 및 이의 용도 |
WO2019004800A3 (ko) * | 2017-06-30 | 2019-05-23 | 주식회사 차바이오텍 | 줄기세포 유래 피부전구세포 배양액 및 이의 제조 방법 |
RU2754043C2 (ru) * | 2017-06-30 | 2021-08-25 | Чха Байотек Ко., Лтд. | Культуральная среда клеток-предшественников кожи, происходящих из стволовых клеток, и способ ее получения |
US11773370B2 (en) | 2017-06-30 | 2023-10-03 | Cha Biotech Co., Ltd. | Stem cell-derived skin precursor cell culture medium and preparation method therefor |
KR20190003303A (ko) * | 2017-12-26 | 2019-01-09 | (주) 차바이오에프앤씨 | 피부줄기세포 배양액을 포함하는 피부 노화 예방 또는 개선용 조성물 및 이의 용도 |
KR102178778B1 (ko) * | 2017-12-26 | 2020-11-13 | (주) 차바이오에프앤씨 | 피부줄기세포 배양액을 포함하는 피부 노화 예방 또는 개선용 조성물 및 이의 용도 |
Also Published As
Publication number | Publication date |
---|---|
EP2865749A1 (en) | 2015-04-29 |
CN104603263A (zh) | 2015-05-06 |
KR101523040B1 (ko) | 2015-05-26 |
JP2015526067A (ja) | 2015-09-10 |
AU2013281596A1 (en) | 2014-12-04 |
ZA201408915B (en) | 2015-11-25 |
US20150118748A1 (en) | 2015-04-30 |
KR20140000945A (ko) | 2014-01-06 |
MX2014014337A (es) | 2015-02-20 |
HK1206781A1 (en) | 2016-01-15 |
BR112014031874A2 (pt) | 2017-08-01 |
EP2865749A4 (en) | 2015-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014003319A1 (ko) | 고농도의 줄기세포 제조방법 | |
WO2013157850A1 (ko) | 혈관 내 투여에 적합한 크기를 가지는 줄기세포의 제조방법 | |
CN108251359B (zh) | 一种间充质干细胞无血清培养基及培养方法 | |
WO2013154404A1 (ko) | 줄기세포의 파쇄 및 응집 방지 방법 및 조성물 | |
JP6267324B2 (ja) | 幹細胞の再生能向上のための培地組成物及びこれを利用した幹細胞の培養方法 | |
WO2015105356A1 (ko) | 순수 영양막층으로부터 유래된 줄기세포 및 이를 포함하는 세포치료제 | |
KR20130061658A (ko) | 줄기세포를 젊게 만들기 위한 배지 조성물 | |
WO2015105357A1 (ko) | 영양막 기저층으로부터 유래된 줄기세포 및 이를 포함하는 세포치료제 | |
WO2016068596A1 (ko) | 줄기세포 배양을 위한 배지조성물 | |
US11840706B2 (en) | Composition and method for generating a desired cell type and/or tissue type from hair follicular stem cells | |
KR20090056925A (ko) | 탈락막 또는 지방 유래 줄기세포를 함유하는 요실금의 세포치료제 | |
KR20120057784A (ko) | 줄기세포의 안정성 증진용 조성물 | |
CN115125192B (zh) | 一种骨髓上清液及其在细胞培养中的应用 | |
JP2005287479A (ja) | 組織幹細胞採取方法及びそれを利用した装置 | |
KR101134456B1 (ko) | 돼지 제대 유래 중간엽 줄기세포의 생산효율을 높이는 배양배지 조성물 및 세포 치료제 | |
KR102218126B1 (ko) | 소변 유래 줄기세포의 미분화능을 유지하는 방법 | |
CN114504596A (zh) | 多能干细胞来源的间充质干细胞在治疗银屑病中的应用 | |
CN117165512A (zh) | 一种将自体间充质干细胞诱导为胰岛β样细胞的方法 | |
WO2016125936A1 (ko) | 감태 추출물을 포함하는 중간엽 줄기세포 배양용 배지 조성물 | |
JP2005287478A (ja) | ヒト脂肪前駆細胞株及びその利用方法 | |
WO2016088933A1 (ko) | 지방-유래 중간엽 줄기세포로부터 유도만능 줄기세포를 제조하여 간세포로 분화 시키는 방법 | |
KR20150018204A (ko) | 생착능이 증가된 줄기세포 응집체의 제조 방법, 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13810037 Country of ref document: EP Kind code of ref document: A1 |
|
REEP | Request for entry into the european phase |
Ref document number: 2013810037 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013810037 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2014/014337 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14405320 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2013281596 Country of ref document: AU Date of ref document: 20130523 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2015520000 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014031874 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014031874 Country of ref document: BR Kind code of ref document: A2 Effective date: 20141218 |